Perinatal hypoxic ischemic encephalopathy: Current and future treatments

International Pediatrics

Volumn 15, Issue 3, 2000, Pages 138-146

  Legido, A ^a   Katsetos, C D ^a   Mishra, O P ^a   Delivoria Papadopoulos, M ^a  

^a ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

Author keywords

Hypoxic ischemic encephalopathy

Indexed keywords

ADENOSINE; ADENOSINE TRIPHOSPHATE; ALLOPURINOL; ALPHA TOCOPHEROL; ASCORBIC ACID; BARBITURIC ACID DERIVATIVE; CALBINDIN; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; DIZOCILPINE; FLUNARIZINE; GLUCOSE; GROWTH FACTOR; IBOTENIC ACID; INDOMETACIN; LACTIC ACID; MAGNESIUM SULFATE; MONOSIALOGANGLIOSIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; NICARDIPINE; NIMODIPINE; OXIPURINOL; PHENOBARBITAL; PROPRANOLOL; SOMATOMEDIN C; THIOPENTAL; TIRILAZAD; UNINDEXED DRUG; XANTHINE OXIDASE; XANTHINE OXIDASE INHIBITOR;

ANAEROBIC METABOLISM; APOPTOSIS; BRAIN CIRCULATION; BRAIN EDEMA; BRAIN ISCHEMIA; BRAIN PERFUSION; CALCIUM CELL LEVEL; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; GENE THERAPY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLACTATEMIA; HYPOGLYCEMIA; HYPOTENSION; HYPOTHERMIA; NERVE INJURY; NEUROPROTECTION; NEWBORN DISEASE; NONHUMAN; PERINATAL ASPHYXIA; REVIEW; SEIZURE; TREATMENT PLANNING;

EID: 0033812819     PISSN: 08856265     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Perinatal hypoxic-ischemic encephalopathy: Current advances in diagnosis and treatment
2. Hypoxic-ischemic encephalopathy
3. Hypoxic-ischemic cerebral injury in the newborn
4. Postasphyxial management of the newborn
5. Multiple organ involvement in perinatal asphyxia
6. Pathophysiology of perinatal hypoxic-ischemic encephalopathy
7. Animal models of perinatal asphyxia; contributions, contradictions, clinical relevance
8. Pathophysiology of perinatal asphyxia
9. Potential new therapies for perinatal cerebral hypoxia-ischemia
10. Neuronal death after perinatal asphyxia
11. Hypoxic-ischemic brain injury in the newborn. Cellular mechanisms and potential strategies for neuroprotection
12. Interventions for perinatal hypoxic-ischemic encephalopathy
13. Mechanisms of cerebral injury in perinatal asphyxia and strategies for prevention
14. Cellular mechanisms of hypoxic injury in the developing brain
15. Hypoxic-ischemic brain injury: Advancements in the understanding of mechanisms and potential avenues for therapy
16. Recent advances in developing neuroprotective strategies for perinatal asphyxia
17. Preserving brain function during neonatal asphyxia
18. Neuroprotection and perinatal brain care: The field of the future, currently going nowhere
19. An international network for evaluating neuroprotective therapy after severe birth asphyxia
20. Cerebral protection by barbiturate anesthesia; use after middle cerebral artery occlusion in Java monkeys
21. Thiopental amelioration of brain damage after global ischemia in monkeys
22. High-dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: A randomized, prospective study with three-year follow-up
23. Use of barbiturate therapy in severe perinatal asphyxia: A randomized control trial
24. Management of the asphyxiated full term infant
25. Magnesium reduces N-methyl-D-aspartate (NMDA)-mediated brain injury in perinatal rats
26. Prevention by magnesium of excitotoxic neuronal death in the developing brain: An animal model of clinical intervention studies
27. Magnesium sulphate therapy during asphyxia in near term lambs does not compromise the fetus but does not reduce cerebral injury
28. Magnesium sulphate after transient hypoxia-ischemia fails to prevent delayed cerebral energy failure in the newborn piglet
29. Can magnesium sulphate reduce the risk of cerebral palsy in very low birth weight infants?
30. Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial
31. Is tocolytic magnesium sulphate associated with increased total pediatric mortality?
32. Tocolytic magnesium sulphate and paediatric mortality
33. Reduction of perinatal hypoxic-ischemic brain damage with allopurinol
34. Allopurinol preserves cerebral energy metabolism during perinatal hypoxic-ischemia: A 31P NMR study in anaesthetized immature rats
35. Reduction of perinatal brain damage with oxypurinol treatment after hypoxic-ischemic injury
36. Randomized controlled trial of allopurinol prophylaxis in very preterm infants
37. Effect of allopurinol on postasphyxial free radical formation, cerebral hemodynamics, and electrical brain activity
38. Flunarizine limits hypoxia-ischemia induced morphologic injury in immature rat brain
39. Flunarizine, a calcium channel antagonist, is not neuroprotective when given after hypoxia-ischemia in the infant rat
40. Neuroprotection by the novel calcium antagonist PCA50938, nimodipine and flunarizine in gerbil global brain ischemia
41. Flunarizine in stroke treatment (FIST): A double blind, placebo-controlled trial in Scandinavia and the Netherlands
42. Reduction of infarct size by intra-arterial nimodipine administered at reperfusion in a rat model of partially reversible brain focal ischemia
43. Neuroprotective properties of a protein kinase inhibitor againstischaemia-induced neuronal damage in rats and gerbils
44. Effect of nimodipine on systemic, renal, and cerebral haemodynamics after a mild hypoxic-ischemic insult in newborn piglets
45. A controlled trial of nimodipine in acute ischemic stroke
46. Effect of nimodipine on memory after cerebral infarction
47. The use of a calcium-channel blocker, nicardipine, for severely asphyxiated newborn infants
48. Anti-oxidant enzymes in fetal guinea pig brain during development and the effect of maternal hypoxia
49. Ascorbate attenuates the systemic kainate-induced neurotoxicity in the rat hippocampus
50. Administration of antioxidants to the mother after onset of fetal bradycardia ameliorates fetal brain injury in rabbits
51. Ascorbate neurotoxicity in cortical cell culture
52. Evidence for the safety of ascorbic acid administration to the premature infant
53. Dietary vitamin E levels affect outcome of permanent focal cerebral ischemia in rats
54. Protective effect of vitamin E in a rat model of cerebral ischemia
55. Alpha-tocopherol supports the survival and neurite extension of neurons cultured from various regions of fetal rat brain
56. Vitamin E prevents apoptosis in cortical neurons during hypoxia
57. The 'pharmacology' of neuronal rescue with cerebral hypothermia
58. The use of hypothermia: A role in the treatment of neonatal asphyxia?
59. Moderate hypothermia mitigates neuronal damage in the rat brain when initiated several hours following transient cerebral ischemia
60. Brief post-Hl hypothermia markedly delays neonatal brain injury
61. Mild hypothermia after severe transient hypoxia-ischemia ameliorates delayed cerebral energy failure in the newborn piglet
62. New approaches to preventing brain damage during asphyxia
63. Cerebral hypothermia is not neuroprotective when started after postischemic seizures in fetal sheep
64. Selective head cooling in newborn infants after perinatal asphyxia: A safety study
65. 1 protects the brain of fetal sheep against hypoxic-ischemic injury without causing systemic compromise
66. 1 treatment after a hypoxic-ischemia episode reduces the vulnerability of the fetal sheep brain to subsequent injuries
67. 1. Efficacy and safety results of the early stroke trial
68. 1 ganglioside inhibits ischemic release of amino acid neurotransmitters from rat cortex
69. Nerve growth factor protects the neonatal brain against hypoxic-ischemic injury
70. Marked age-dependent neuroprotection by brain-derived neurotrophic factor against neonatal hypoxic-ischemic brain injury
71. The effects of IGF-1 treatment after hypoxic-ischemic brain injury in adult rats
72. Insulin-like growth factor-1 is a potent neuronal rescue agent following hypoxic-ischemic injury in fetal lambs
73. Selective neuroprotective effects with insulin-like growth factor-1 in phenotypic striatal neurons following ischemic brain injury in fetal sheep
74. Bcl-2 and the regulation of programmed cell death
75. Expression of bcl-2 from a defective herpes simplex virus-1 vector limits neuronal death in focal cerebral ischemia
76. Overexpression of bcl-2 with herpes simplex virus vectors protects CNS neurons against neurological insults in vitro and in vivo
77. Overexpression of bcl-2 in transgenic mice protects neurons from naturally occurring death and experimental ischemia
78. Herpes simplex viral vectors expressing bcl-2 are neuroprotective when delivered after a stroke
79. Alterations of calbindin-D(28k) localization in cerebellar purkinje cells in the hypoxic guinea pig fetus at term
80. Calbindin-D(28k) over expression using gene transfer therapy improves striatal neuron survival following transient focal cerebral ischemia
81. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy